Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Children With Severe Uncontrolled Asthma (HORIZON)
NCT06023589Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Annualized severe asthma exacerbation rate at 52 weeks. Started Aug 2023; status: recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06023589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023589.